Berman Consulting, Wayland, Massachusetts, USA.
Early CVRM, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Nucleic Acid Ther. 2023 Oct;33(5):287-305. doi: 10.1089/nat.2023.0011. Epub 2023 Aug 17.
This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinical studies. In general, the recommended approach is similar to that for small molecule drugs. However, some differences in timing and/or scope may be warranted due to the greater consistency of results across ON classes as compared with the diversity among small molecule classes. For some types of studies, a platform-based approach may be appropriate; once sufficient data are available for the platform, presentation of these data should be sufficient to support development of additional ONs of the same platform. These recommendations can serve as a starting point for nonclinical study design and foundation for discussions with regulatory agencies.
本白皮书总结了寡核苷酸安全工作组吸收、分布、代谢和排泄(ADME)小组委员会的建议,用于描述非临床研究中寡核苷酸(ON)治疗药物的吸收、分布、代谢和排泄特征。一般来说,推荐的方法与小分子药物相似。然而,由于与小分子药物种类的多样性相比,ON 种类的结果更具一致性,因此在时间和/或范围上可能需要进行一些调整。对于某些类型的研究,基于平台的方法可能是合适的;一旦为平台获得了足够的数据,这些数据的呈现应该足以支持同一平台的其他 ON 的开发。这些建议可以作为非临床研究设计的起点,并为与监管机构的讨论奠定基础。